NL-OMON44294
已完成
不适用
A first-in-human, single-centre, placebo-controlled, randomized, double-blind study in healthy subjects to evaluate safety, tolerability, pharmacokinetics and food effect after oral single and multiple ascending dosing of KAND567 - KAN0001 (CS0276)
概览
- 阶段
- 不适用
- 干预措施
- 未指定
- 疾病 / 适应症
- MS
- 发起方
- Kancera AB
- 入组人数
- 98
- 状态
- 已完成
- 最后更新
- 2年前
概览
简要总结
暂无简介。
研究者
入排标准
入选标准
- •Healthy male and female
排除标准
- •Clinical significant abnormalities at medical research
结局指标
主要结局
未指定
相似试验
已完成
1 期
A study to assess the safety and tolerability of ACI-3024 and how the drug affects and interacts with the bodyISRCTN18150742AC Immune (Switzerland)80
进行中（未招募）
1 期
2-part study of DCR-PHXC in healthy volunteers and in primary hyperoxaluria patientsEUCTR2017-003534-89-NLDicerna Pharmaceuticals Inc43
进行中（未招募）
1 期
2-part study of DCR-PHXC in healthy volunteers and in primary hyperoxaluria patientsPrimary HyperoxaluriaMedDRA version: 20.1Level: PTClassification code 10020703Term: HyperoxaluriaSystem Organ Class: 10038359 - Renal and urinary disordersTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]EUCTR2017-003534-89-GBDicerna Pharmaceuticals Inc43
进行中（未招募）
1 期
2-part study of DCR-PHXC in healthy volunteers and in primary hyperoxaluria patientsPrimary HyperoxaluriaMedDRA version: 20.1 Level: PT Classification code 10020703 Term: Hyperoxaluria System Organ Class: 10038359 - Renal and urinary disordersTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]EUCTR2017-003534-89-FRDicerna Pharmaceuticals Inc41
进行中（未招募）
1 期
2-part study of DCR-PHXC in healthy volunteers and in primary hyperoxaluria patientsEUCTR2017-003534-89-DEDicerna Pharmaceuticals Inc41